Literature DB >> 12970301

Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey.

Mathias Leblanc1, Claude Labrie, Alain Bélanger, Bernard Candas, Fernand Labrie.   

Abstract

We have studied the pharmacokinetics of dehydroepiandrosterone (DHEA) administered orally (PO), i.v., and during a continuous i.v. infusion in ovariectomized cynomolgus monkeys under suppression of adrenal DHEA secretion with dexamethasone. The glucocorticoid induced a rapid suppression of serum cortisol, DHEA, and DHEA-sulfate (DHEA-S) as well as their metabolites, thus permitting to use this model to study the pharmacokinetic parameters of DHEA and its metabolites without significant interference by endogenous steroid levels. After a single 10 mg i.v. dose of DHEA, the metabolic clearance rate and terminal half-life of DHEA were 99.9 +/- 9.1 liter/d and 4.5 +/- 0.3 h, respectively. Following a 50-mg DHEA PO dose, systemic availability was only 3.1 +/- 0.4%. As shown by their high conversion ratios, the major circulating metabolites of DHEA are DHEA-S, androsterone glucuronide, and androstane-3 alpha,17 beta-diol-glucuronide. The conversion ratios of androst-5-ene-3 beta,17 beta-diol, testosterone, dihydrotestosterone, and androstenedione are, in comparison, small. No transformation to estrogens could be detected in the circulation after either i.v. or PO DHEA administration. The present data indicate that DHEA is transformed predominantly into androgens in peripheral tissues in ovariectomized cynomolgus monkeys with minimal (androgens) or no (estrogens) release of the bioactive steroids in the circulation. Furthermore, the present study supports the importance of measuring circulating androgen glucuronide derivatives to assess hormonal exposure of peripheral tissues to androgens after DHEA administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970301     DOI: 10.1210/jc.2003-022012

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Phase I and Phase II clinical trials of androst-5-ene-3β,7β,17β-triol.

Authors:  Dwight R Stickney; Clarence N Ahlem; Elizabeth Morgan; Christopher L Reading; Nanette Onizuka; James M Frincke
Journal:  Am J Transl Res       Date:  2011-04-12       Impact factor: 4.060

Review 2.  Defining adrenarche in the rhesus macaque (Macaca mulatta), a non-human primate model for adrenal androgen secretion.

Authors:  A J Conley; B C Moeller; A D Nguyen; S D Stanley; T M Plant; D H Abbott
Journal:  Mol Cell Endocrinol       Date:  2010-12-22       Impact factor: 4.102

3.  Studies of the pharmacology of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol, a synthetic anti-inflammatory androstene.

Authors:  Clarence N Ahlem; Michael R Kennedy; Theodore M Page; Christopher L Reading; Steven K White; John J McKenzie; Phaedra I Cole; Dwight R Stickney; James M Frincke
Journal:  Int J Clin Exp Med       Date:  2011-04-23

4.  HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression.

Authors:  Douglas Conrad; Angela Wang; Raymond Pieters; Ferdinando Nicoletti; Katia Mangano; Anna M van Heeckeren; Steven K White; James M Frincke; Christopher L Reading; Dwight Stickney; Dominick L Auci
Journal:  J Inflamm (Lond)       Date:  2010-10-30       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.